NCT07664657尚未招募不适用
An Open-Label, Randomized, Single Dose Study, to Assess Dose Proportionality and Pharmacokinetic Linearity of Saninova Tablets Manufactured by Sichuan Credit Pharmaceutical Co., Ltd, China In Healthy Participants Under Fasting Conditions.
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- 1. Pharmacokinetic analysis
研究概览
简要总结
An open-label, randomized, single dose study to assess dose proportionality and pharmacokinetic linearity in healthy participants under fasting condition.
详细描述
This is An Open-Label, Randomized, Single Dose Study, to assess Dose Proportionality and Pharmacokinetic Linearity of Saninova Tablets in Healthy Participants under Fasting Conditions. A total number of 32 normal healthy adult human subjects will be included in the study. Vitamin C (Ascorbic acid), Vitamin B2 (Riboflavin) and Astragaloside IV in plasma samples will be assayed using a validated method LC-MS/MS analytical method.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participation is truly voluntarily.
- •Healthy adult, human Participants between 18 to 45 years of age (both inclusive) and weighing at least 50 kgs.
- •Having a Body Mass Index (BMI) between 18.50 and 30.00 Kg/m2 (both inclusive) calculated as weight in kg / height in m
- •Have normal clinically findings as judged by investigators during screening within 28 days prior to administration of first dose of study drug, medical history and examination, laboratory evaluations, 12-lead ECG recordings, chest X-ray will be conducted.
- •If any participants, blood pressure, vitals within the limits that participant will include into the study.
- •Able to comply with the study procedures, in the opinion of the PI/CI.
- •Non-smoker and non-alcoholic.
- •Able to give written consent for participation in the study.
- •Male participants who are willing to maintain the abstain sexual contact by maintaining the birth control such as, a latex or synthetic condom, Vasectomy and tubal sterilization every time they have sexual intercourse with a female of reproductive potential during treatment and for one week after the final dose.
- •For Female Participants
- •Participant having negative β-hCG (serum pregnancy or urine pregnancy) test and Hormone assay (FSH).
- •Child bearing potential willing to practice an acceptable method of birth control for the duration of the study and until three weeks after the last dose as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence from the date of screening until the completion of study and for one week after the final dose, or
- •Post-menopausal for at least 1 year, or.
- •Female participants should not be pregnant or lactating, and, should practice abstention or contraception during the study and for one week after the final dose of the study. Gynecological and breast examinations (for females) will be done before check in of each cohort only
排除标准
- •History or presence of Hypersensitivity to ascorbic acid or any component of the formulation.
- •Participants having history of oxalate kidney stones, renal disorders, iron overload disorders eg: hemochromatosis, Glucose-6-Phosphate Dehydrogenase deficiency.
- •History or presence of certain laboratory tests eg: blood glucose and occult blood measurements, hemolysis, scurvy.
- •History or presence of concomitant use of Warfarin, Aspirin, Deferoxamine, Estrogen-containing oral contraceptives, Paracetamol.
- •History or presence of Hypersensitivity to riboflavin or any formulation component.
- •History or presence of bright yellow discoloration of urine, certain diagnostic tests, Hypersensitivity reactions.
- •History or presence of severe liver dysfunction, severe hepatic impairment, Chronic alcohol consumption.
- •History or presence of concomitant use of Chlorpromazine, Imipramine, oral contraceptives, Methotrexate and Probenecid.
- •History or presence of Hypersensitivity to Astragalus or related plant species.
- •Participants having history of autoimmune diseases eg: Systemic Lupus Erythematosus, Rheumatoid Arthritis, or Multiple Sclerosis, immunosuppressive therapy e.g: Cyclosporine.
- •Participants having history of bleeding disorders, anticoagulant therapy.
- •History or presence of hypotension or hypoglycemia.
- •History or presence of concomitant use of Cyclosporine, antihypertensive drugs e.g: Amlodipine, antidiabetic agents e.g: Metformin, anticoagulants or antiplatelet drugs e.g: Clopidogrel, diuretics.
- •If any participants, blood pressure, vitals beyond the limits that participant will be excluded from the study.
- •Female participants with positive β-hCG (serum pregnancy) at the time of screening and prior to check-In.
- •Habituated to drinking tea or coffee (more than 5 cups/day) or inability to abstain during sample collection.
- •Habituated to tobacco/tobacco containing products or inability to abstain during entire course of the study.
- •A positive result for hepatitis B & C, HIV antibody and syphilis (VDRL) tests.
- •Use of any recreational drugs or history of drug addiction or testing positive for urine drugs of abuse prior to check-In.
- •History of difficulty with donating blood.
- •Donation of blood/ Plasma (1 unit: 350 mL / 450 mL) within 90 days prior to sample collection.
- •The receipt of an investigational product or participation in a drug research study within a period of 90 days prior to the sample collection.
- •Study participants having any deformity that will affect venous access for Cannulation.
- •Study participants having any history of surgery in the previous six months.
- •Difficulty in swallowing investigational medicine products.
- •Known or suspected increased susceptibility to infection.
- •Presence of any flu symptoms.
- •Presence of any clinically significant abnormal values during screening.
- •Recent history of dehydration from diarrhoea, vomiting or any other reason within period of 07 days prior to study Check-In.
- •Use of any prescribed or OTC medicinal products including vitamins, herbal supplements and minerals during the within two weeks prior to investigational products administration in period I.
- •Female participants who have used implanted or injected hormonal contraceptives within 14 days before dosing.
- •Female participants are currently breast-feeding.
研究组 & 干预措施
Test Arm
Experimental
Saninova Tablets (vitamin C, vitamin B2, Astragalus Root dry extract etc.)
干预措施: Vitamin C, Vitamin B2, Astragalus Root dry extract etc (Dietary Supplement)
结局指标
主要结局
1. Pharmacokinetic analysis
时间窗: Pharmacokinetic plasma samples collected over 72 hr for Vitamin C. Pharmacokinetic plasma samples collected over 12 hr for Vitamin B2. Pharmacokinetic plasma samples collected over 24 hr for Astragaloside IV.
Vitamin C (Ascorbic acid), Vitamin B2 (Riboflavin), Astragaloside IV in plasma samples will be assayed using a validated method LC-MS/MS analytical method
1. Pharmacokinetic analysis
时间窗: Pharmacokinetic plasma samples collected over 72 hours for Vitamin C. Pharmacokinetic plasma samples collected over 12 hours for Vitamin B2. Pharmacokinetic plasma samples collected over 24 hours for Astragaloside IV.
Vitamin C (Ascorbic acid), Vitamin B2 (Riboflavin), Astragaloside IV in plasma samples will be assayed using a validated method LC-MS/MS analytical method
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
The Pharmacokinetics, Safety and Tolerability study of Brexpiprazole 15.3 mg for extended-Release Injection in Subjects with Schizophrenia.CTRI/2025/01/079051Bostal Drug Delivery Co., Ltd.12
尚未招募
1 期
Assessment of Dutasteride Topical Solution in Male Androgenetic AlopeciaAndrogenetic AlopeciaNCT07490327Moogene Medi Co., Ltd30
进行中（未招募）
1 期
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension 90 mg in Individuals with Schizophrenia.CTRI/2025/02/081389Bostal Drug Delivery Co., Ltd.12
招募中
1 期
A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment PatientsNCT07347808Vincentage Pharma Co., Ltd16
已完成
不适用
An Open Label Balanced Randomized Single Dose Two Treatment Two Sequence Two Period Two Way Crossover Oral Pharmacokinetic Study Comparing Cinnamon Bark Extract 15 Mg Cinnamaldehyde CapsuleCTRI/2024/09/074434Nutriventia Limited12